Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: Report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes

American Journal of Surgical Pathology

Volumn 38, Issue 1, 2014, Pages 23-33

  Skálová, Alena ^a,b   Vanecek, Tomas ^c   Majewska, Hanna ^e   Laco, Jan ^d   Grossmann, Petr ^c   Simpson, Roderick H W ^f   Hauer, Lukas ^a   Andrle, Pavel ^a   Hosticka, Lubor ^a   Branžovský, Jindrich ^a   Michal, Michal ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Bioptic Laboratory   (Czech Republic)

^c Molecular Pathology Laboratory   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

ETV6 NTRK3; fusion; high grade transformation; mammary analogue secretory carcinoma; MASC; salivary gland

Indexed keywords

BETA CATENIN; CCND1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYCLIN D1; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETV6 NTRK3 FUSION PROTEIN, HUMAN; ETV6-NTRK3 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BIOPSY; CANCER GRADING; CARCINOMA; CASE REPORT; CELL TRANSFORMATION; CHEMISTRY; FATALITY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PAROTID GLAND TUMOR; PATHOLOGY; PROGNOSIS; TIME;

AGED; BETA CATENIN; BIOPSY; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DNA MUTATIONAL ANALYSIS; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PAROTID NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891628067     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000088     Document Type: Article

References (40)

1. Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599-608.
2. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367-376.
3. Fehr A, Loning T, Stenman G. Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Letter to Editor. Am J Surg Pathol. 2011;35:1600-1602.
4. Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Arch. 2011;459: 117-118.
5. Lei Y, Chiosea SI. Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. Head Neck Pathol. 2012;6:166-170.
6. Connor A, Perez-Ordoñ ez B, Shago M, et al. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012;36:27-34.
7. Chiosea SI, Griffith C, Assad A, et al. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. Am J Surg Pathol. 2012;36:343-350.
8. Chiosea SI, Griffith C, Assad A, et al. Clinicopathological characterization of mammary analogue carcinoma of salivary glands. Histopathology. 2012;61:387-394.
9. Laco J, S? vajdler M Jr, Andrejs J, et al. Mammary analogue secretory carcinoma of salivary glands: a report of 2 cases with expression of basal/myoepithelial markers (calponin, CD10 and p63 protein). Pathol Res Pract. 2013;209:167-172.
10. Jung MJ, Song JS, Kim SY, et al. Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol. 2013;47:36-43.
11. Rastatter JC, Jatana KR, Jennings LJ, et al. Mammary analogue secretory carcinoma of parotid gland in a pediatric patient. Otolaryngol Head Neck Surg. 2012;146:514-515.
12. Petersson F, Lian D, Chau YP, et al. Mammary analogue secretory carcinoma: the first submandibular case reported including findings on fine needle aspiration cytology. Head Neck Pathol. 2012;6:135-139.
13. Ito S, Ishida E, Skalova A, et al. Short communication: a case of mammary analogue secretory carcinoma of parotid gland. Pathol Int. 2012;62:149-152.
14. Kratochvil FJ, Stewart JCB, Moore SR. Mammary analog secretory carcinoma of salivary glands: a report of 2 cases in the lip. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:630-635.
15. Levine P, Fried K, Krevitt LD, et al. Aspiration biopsy of mammary analogue secretory carcinoma of accessory parotid gland: another diagnostic dilemma in matrix-containing tumors of the salivary glands. Diagn Cytopathol. 2012. doi: 10.1002/dc.22886 [Epub ahead of print].
16. Griffith CC, Stelow EB, Saqi A, et al. The cytological features of mammary analogue secretory carcinoma. A series of 6 molecularly confirmed cases. Cancer Cytopathol. 2013;121:234-241.
17. Skalova A, Sima R, Vanecek T, et al. Acinic cell carcinoma with high-grade transformation. Am J Surg Pathol. 2009;33:1137-1145.
18. Schwarz S, Zenk J, Muller M, et al. The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology. 2012;61:395-408.
19. Viswanatha DS, Foucar K, Berry BR, et al. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol. 2000;13:825-833.
20. Gaffney R, Chakerian A, O'Connell JX, et al. Novel fluorescent ligase detection reaction and flow cytometric analysis of SYT-SSX fusions in synovial sarcoma. J Mol Diagn. 2003;5:127-135.
21. Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol. 2000;9:1-8.
22. van Dongen JJ, Langerak AW, Bru? ggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
23. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
24. Pugh TJ, Bebb G, Barclay L, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer. 2007;7:128.
25. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
26. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004;64:8534-8540.
27. Chenevert J, Duvvuri U, Chiosea S, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25:919-929.
28. Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcoma. Cancer. 1971;28:461-466.
29. Evans HL. Liposarcomas and atypical lipomatous tumors: a study of 66 cases followed for a minimum of 10 years. Surg Pathol. 1988;1:41-54.
30. Cheuk W, Chan JKC, Ngan RKC. Dedifferentiation in adenoid cystic carcinoma of salivary gland. An uncommon complication associated with accelerated clinical course. Am J Surg Pathol. 1999; 23:465-472.
31. Simpson RHW, Reis-Filho JS, Pereira EM, et al. Polymorphous lowgrade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology. 2002;41:250-259.
32. Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and aerodigestive tract. Am J Surg Pathol. 2007;31:44-57.
33. Nagao T, Gaffey TA, Serizawa H, et al. Dedifferentiated adenoid cystic carcinoma a clinicopathologic study of 6 cases. Mod Pathol. 2003;16:1265-1272.
34. Di Palma S, Corletto V, Lavarino C, et al. Unilateral aneuploid dediferrentiated acinic cell carcinoma associated with bilateral low grade diploid acinic cell carcinoma of the parotid gland. Virchows Arch. 1999;434:361-365.
35. Bishop JA, Yonescu R, Batista D, et al. Most nonparotid "acinic cell carcinomas" represent mammary analog secretory carcinomas. Am J Surg Pathol. 2013;37:1053-1057.
36. Chi HT, Ly BT, Kano Y, et al. ETV6-NTRK3 as a therapuetic target of small molecule inhibitor PKC412. Biochem Biophys Res Commun. 2012;429:87-92.
37. Tognon CE, Somasiri AM, Evdokimova VE, et al. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res. 2011;71:1060-1070.
38. Jabber Al-Obaidi MS, Martineau M, Bennett CF, et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia. 2002;16:669-674.
39. Walz C, Erben P, Ritter M, et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMSlike tyrosine kinase 3. Blood. 2011;118:2239-2242.
40. O'Brien SG, Vieira SA, Connors S, et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood. 2002;99:3465-3467.